{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:46:41Z","timestamp":1791935201759,"version":"4.3.4"},"reference-count":265,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["Grant No. 7232132"],"award-info":[{"award-number":["Grant No. 7232132"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["Grant No. 2023YFC2507002"],"award-info":[{"award-number":["Grant No. 2023YFC2507002"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08892-7","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:04:16Z","timestamp":1789067056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liquid biopsy in bladder cancer: towards precision oncology"],"prefix":"10.1186","volume":"24","author":[{"given":"Can","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuze","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabo","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Guo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0381-5585","authenticated-orcid":false,"given":"Xiongjun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"5","key":"8892_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"LMC van Hoogstraten","year":"2023","unstructured":"van Hoogstraten LMC, Vrieling A, van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol. 2023;20(5):287\u2013304.","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"8892_CR2","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-17-1140","volume":"23","author":"G Vandekerkhove","year":"2017","unstructured":"Vandekerkhove G, Todenh\u00f6fer T, Annala M, Struss WJ, Wong A, Beja K, Ritch E, Brahmbhatt S, Volik SV, Hennenlotter J, et al. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clin Cancer Res. 2017;23(21):6487\u201397.","journal-title":"Clin Cancer Res"},{"key":"8892_CR3","doi-asserted-by":"publisher","first-page":"992118","DOI":"10.3389\/fonc.2022.992118","volume":"12","author":"Z Xia","year":"2022","unstructured":"Xia Z, Fu X, Li J, Wu J, Niu C, Xu Y, Wang H, Yuan X, Tang L. Prognostic value of pretreatment serum albumin-globulin ratio in urothelial carcinoma: A systematic review and meta-analysis. Front Oncol. 2022;12:992118.","journal-title":"Front Oncol"},{"issue":"1","key":"8892_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"8892_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.eururo.2021.07.019","volume":"80","author":"A Kartolo","year":"2021","unstructured":"Kartolo A, Kassouf W, Vera-Badillo FE. Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time? Eur Urol. 2021;80(6):679\u201381.","journal-title":"Eur Urol"},{"issue":"3","key":"8892_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Hern\u00e1ndez V, Kaasinen E, Palou J, Roupr\u00eat M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71(3):447\u201361.","journal-title":"Eur Urol"},{"issue":"11","key":"8892_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/iju.14082","volume":"26","author":"T Yoshida","year":"2019","unstructured":"Yoshida T, Kates M, Fujita K, Bivalacqua TJ, McConkey DJ. Predictive biomarkers for drug response in bladder cancer. Int J Urol. 2019;26(11):1044\u201353.","journal-title":"Int J Urol"},{"issue":"1","key":"8892_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9\u201316.","journal-title":"Br J Cancer"},{"issue":"2","key":"8892_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","volume":"183","author":"BY Nabet","year":"2020","unstructured":"Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, et al. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. 2020;183(2):363\u2013e376313.","journal-title":"Cell"},{"key":"8892_CR10","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3389\/fimmu.2020.02023","volume":"11","author":"Y Xu","year":"2020","unstructured":"Xu Y, Fu Y, Zhu B, Wang J, Zhang B. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Front Immunol. 2020;11:2023.","journal-title":"Front Immunol"},{"issue":"2","key":"8892_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/cac2.12129","volume":"41","author":"HM Huang","year":"2021","unstructured":"Huang HM, Li HX. Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer. Cancer Commun (Lond). 2021;41(2):91\u2013108.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"8892_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19336918.2024.2395807","volume":"18","author":"K Kurma","year":"2024","unstructured":"Kurma K, Eslami SZ, Alix-Panabi\u00e8res C, Cayrefourcq L. Liquid biopsy: paving a new avenue for cancer research. Cell Adh Migr. 2024;18(1):1\u201326.","journal-title":"Cell Adh Migr"},{"key":"8892_CR13","doi-asserted-by":"publisher","first-page":"958360","DOI":"10.3389\/fimmu.2022.958360","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu Z, Kong Y, Dang Q, Weng S, Zheng Y, Ren Y, Lv J, Li N, Han Y, Han X. Liquid Biopsy in Pre-Metastatic Niche: From Molecular Mechanism to Clinical Application. Front Immunol. 2022;13:958360.","journal-title":"Front Immunol"},{"issue":"1","key":"8892_CR14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, Sun T, Wei J. Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther. 2024;9(1):336.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"8892_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of?liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20(2):71\u201388.","journal-title":"Nat Rev Genet"},{"issue":"2","key":"8892_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/PPO.0000000000000308","volume":"24","author":"N Ramalingam","year":"2018","unstructured":"Ramalingam N, Jeffrey SS. Future of Liquid Biopsies With Growing Technological and Bioinformatics Studies: Opportunities and Challenges in Discovering Tumor Heterogeneity With Single-Cell Level Analysis. Cancer J. 2018;24(2):104\u20138.","journal-title":"Cancer J"},{"key":"8892_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-3-030-55035-6_9","volume":"1286","author":"MM Galvis","year":"2021","unstructured":"Galvis MM, Romero CS, Bueno TO, Teng Y. Toward a New Era for the Management of Circulating Tumor Cells. Adv Exp Med Biol. 2021;1286:125\u201334.","journal-title":"Adv Exp Med Biol"},{"key":"8892_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jim.2018.09.011","volume":"463","author":"K Sherwood","year":"2018","unstructured":"Sherwood K, Weimer ET. Characteristics, properties, and potential applications of circulating cell-free dna in clinical diagnostics: a focus on transplantation. J Immunol Methods. 2018;463:27\u201338.","journal-title":"J Immunol Methods"},{"issue":"19","key":"8892_CR19","doi-asserted-by":"publisher","first-page":"9412","DOI":"10.1016\/S0021-9258(18)48095-7","volume":"262","author":"RM Johnstone","year":"1987","unstructured":"Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262(19):9412\u201320.","journal-title":"J Biol Chem"},{"issue":"8","key":"8892_CR20","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781\u201391.","journal-title":"N Engl J Med"},{"issue":"12","key":"8892_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41568-020-00299-w","volume":"20","author":"A M\u00f6ller","year":"2020","unstructured":"M\u00f6ller A, Lobb RJ. The evolving translational potential of small extracellular vesicles in cancer. Nat Rev Cancer. 2020;20(12):697\u2013709.","journal-title":"Nat Rev Cancer"},{"key":"8892_CR22","doi-asserted-by":"crossref","unstructured":"Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921.","DOI":"10.1126\/scitranslmed.aat4921"},{"key":"8892_CR23","doi-asserted-by":"crossref","unstructured":"Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Invest. 2022;132(12):e154941.","DOI":"10.1172\/JCI154941"},{"issue":"3\u20134","key":"8892_CR24","first-page":"241","volume":"142","author":"P Mandel","year":"1948","unstructured":"Mandel P, Metais P. [Nuclear Acids In Human Blood Plasma]. C R Seances Soc Biol Fil. 1948;142(3\u20134):241\u20133.","journal-title":"C R Seances Soc Biol Fil"},{"issue":"24","key":"8892_CR25","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/JCO.21.02615","volume":"40","author":"M Malla","year":"2022","unstructured":"Malla M, Loree JM, Kasi PM, Parikh AR. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. J Clin Oncol. 2022;40(24):2846\u201357.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8892_CR26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccell.2020.03.012","volume":"37","author":"E Kilgour","year":"2020","unstructured":"Kilgour E, Rothwell DG, Brady G, Dive C. Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance. Cancer Cell. 2020;37(4):485\u201395.","journal-title":"Cancer Cell"},{"issue":"2","key":"8892_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","volume":"124","author":"L Keller","year":"2021","unstructured":"Keller L, Belloum Y, Wikman H, Pantel K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2021;124(2):345\u201358.","journal-title":"Br J Cancer"},{"issue":"1\u20132","key":"8892_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","volume":"164","author":"MW Snyder","year":"2016","unstructured":"Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell. 2016;164(1\u20132):57\u201368.","journal-title":"Cell"},{"key":"8892_CR29","doi-asserted-by":"crossref","unstructured":"Reddy T, Esmail A, Chang JC, Ghobrial RM, Abdelrahim M. Utility of cell-free DNA detection in transplant oncology. Cancers (Basel). 2022;14(3):743.","DOI":"10.3390\/cancers14030743"},{"issue":"3","key":"8892_CR30","first-page":"216","volume":"3","author":"H Che","year":"2022","unstructured":"Che H, Stanley K, Jatsenko T, Thienpont B, Vermeesch JR. Expanded knowledge of cell-free DNA biology: potential to broaden the clinical utility. Extracell Vesicles Circ Nucl Acids. 2022;3(3):216\u201334.","journal-title":"Extracell Vesicles Circ Nucl Acids"},{"key":"8892_CR31","doi-asserted-by":"crossref","unstructured":"Ungerer V, Bronkhorst AJ, Uhlig C, Holdenrieder S. Cell-free DNA fragmentation patterns in a cancer cell line. Diagnostics (Basel). 2022;12(8):1896.","DOI":"10.3390\/diagnostics12081896"},{"issue":"2","key":"8892_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/2767-9764.CRC-25-0373","volume":"6","author":"PF Favaro","year":"2026","unstructured":"Favaro PF, Wang Y, McDonald BR, Wang TX, Jadhav S, Cheng HH, Marcinak CT, Pan X, Murtaza M. Comparative Analysis of Cell-Free DNA Fragmentation Patterns in Canines with Sarcoma and Tumor-Free Canines and Humans. Cancer Res Commun. 2026;6(2):310\u20139.","journal-title":"Cancer Res Commun"},{"key":"8892_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12920-015-0107-z","volume":"8","author":"D Chandrananda","year":"2015","unstructured":"Chandrananda D, Thorne NP, Bahlo M. High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA. BMC Med Genomics. 2015;8:29.","journal-title":"BMC Med Genomics"},{"issue":"2","key":"8892_CR34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/1878-0261.13116","volume":"16","author":"S Waldeck","year":"2022","unstructured":"Waldeck S, Mitschke J, Wiesemann S, Rassner M, Andrieux G, Deuter M, Mutter J, L\u00fcchtenborg AM, Kottmann D, Titze L, et al. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer. Mol Oncol. 2022;16(2):527\u201337.","journal-title":"Mol Oncol"},{"key":"8892_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.18632\/oncotarget.28681","volume":"16","author":"MA Lopes","year":"2025","unstructured":"Lopes MA, Cordeiro MER, de Alencar Teles Barreto F, de Souza Moreno L, de Medeiros Silva AA, de Loyola MB, Soares MVA, de Sousa JB, Pittella-Silva F. Assessment of cfDNA release dynamics during colorectal cancer surgery. Oncotarget. 2025;16:29\u201338.","journal-title":"Oncotarget"},{"key":"8892_CR36","doi-asserted-by":"crossref","unstructured":"Cohen R, Pudlarz T, Delattre JF, Colle R, Andr\u00e9 T. Molecular targets for the treatment of metastatic colorectal cancer. Cancers (Basel). 2020;12(9):2350.","DOI":"10.3390\/cancers12092350"},{"key":"8892_CR37","doi-asserted-by":"publisher","first-page":"1423470","DOI":"10.3389\/fmolb.2024.1423470","volume":"11","author":"TF da Silva","year":"2024","unstructured":"da Silva TF, de Azevedo JC Jr., Teixeira EB, Casseb SMM, Moreira FC, de Assump\u00e7\u00e3o PP, Dos Santos SEB, Calcagno DQ. From haystack to high precision: advanced sequencing methods to unraveling circulating tumor DNA mutations. Front Mol Biosci. 2024;11:1423470.","journal-title":"Front Mol Biosci"},{"issue":"4","key":"8892_CR38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/j.gastro.2016.11.048","volume":"152","author":"D Sia","year":"2017","unstructured":"Sia D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology. 2017;152(4):745\u201361.","journal-title":"Gastroenterology"},{"key":"8892_CR39","doi-asserted-by":"crossref","unstructured":"Chidharla A, Rapoport E, Agarwal K, Madala S, Linares B, Sun W, Chakrabarti S, Kasi A. Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis. Int J Mol Sci. 2023;24(12):10230.","DOI":"10.3390\/ijms241210230"},{"issue":"1","key":"8892_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ijc.1434","volume":"94","author":"R von Knobloch","year":"2001","unstructured":"von Knobloch R, Hegele A, Brandt H, Olbert P, Heidenreich A, Hofmann R. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer. 2001;94(1):67\u201372.","journal-title":"Int J Cancer"},{"issue":"3","key":"8892_CR41","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1158\/1078-0432.CCR-0851-3","volume":"10","author":"R von Knobloch","year":"2004","unstructured":"von Knobloch R, Brandt H, Schrader AJ, Heidenreich A, Hofmann R. Molecular serological detection of DNA alterations in transitional cell carcinoma is highly sensitive and stage independent. Clin Cancer Res. 2004;10(3):988\u201393.","journal-title":"Clin Cancer Res"},{"key":"8892_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1749-6632.2001.tb03861.x","volume":"945","author":"M Utting","year":"2001","unstructured":"Utting M, Werner W, M\u00fcller G, Schubert J, Junker K. A possible noninvasive method for the detection of bladder cancer in patients: microsatellite analysis of free DNA in urine and blood. Ann N Y Acad Sci. 2001;945:31\u20135.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"8892_CR43","first-page":"35","volume":"8","author":"M Utting","year":"2002","unstructured":"Utting M, Werner W, Dahse R, Schubert J, Junker K. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin Cancer Res. 2002;8(1):35\u201340.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8892_CR44","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.juro.2007.08.091","volume":"179","author":"J Ellinger","year":"2008","unstructured":"Ellinger J, El Kassem N, Heukamp LC, Matthews S, Cubukluoz F, Kahl P, Perabo FG, M\u00fcller SC, von Ruecker A, Bastian PJ. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol. 2008;179(1):346\u201352.","journal-title":"J Urol"},{"issue":"4","key":"8892_CR45","first-page":"980","volume":"8","author":"G Dom\u00ednguez","year":"2002","unstructured":"Dom\u00ednguez G, Carballido J, Silva J, Silva JM, Garc\u00eda JM, Men\u00e9ndez J, Provencio M, Espa\u00f1a P, Bonilla F. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res. 2002;8(4):980\u20135.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8892_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","volume":"70","author":"K Birkenkamp-Demtr\u00f6der","year":"2016","unstructured":"Birkenkamp-Demtr\u00f6der K, Nordentoft I, Christensen E, H\u00f8yer S, Reinert T, Vang S, Borre M, Agerb\u00e6k M, Jensen JB, \u00d8rntoft TF, et al. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. Eur Urol. 2016;70(1):75\u201382.","journal-title":"Eur Urol"},{"issue":"6","key":"8892_CR47","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","volume":"71","author":"E Christensen","year":"2017","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Nordentoft I, H\u00f8yer S, van der Keur K, van Kessel K, Zwarthoff E, Agerb\u00e6k M, \u00d8rntoft TF, Jensen JB, et al. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. Eur Urol. 2017;71(6):961\u20139.","journal-title":"Eur Urol"},{"issue":"7","key":"8892_CR48","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","volume":"26","author":"A Zviran","year":"2020","unstructured":"Zviran A, Schulman RC, Shah M, Hill STK, Deochand S, Khamnei CC, Maloney D, Patel K, Liao W, Widman AJ, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26(7):1114\u201324.","journal-title":"Nat Med"},{"issue":"6","key":"8892_CR49","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-024-03040-4","volume":"30","author":"AJ Widman","year":"2024","unstructured":"Widman AJ, Shah M, Frydendahl A, Halmos D, Khamnei CC, \u00d8gaard N, Rajagopalan S, Arora A, Deshpande A, Hooper WF, et al. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment. Nat Med. 2024;30(6):1655\u201366.","journal-title":"Nat Med"},{"key":"8892_CR50","doi-asserted-by":"crossref","unstructured":"Wu X, Yao X, Chen Z, Xu H, et al. Re: Iver Nordentoft, Sia Viborg Lindskrog, Karin Birkenkamp-Demtr\u00f6der. Whole-genome mutational analysis for tumor-informed detection of circulating tumor DNA in patients with urothelial carcinoma. Eur Urol. 2024;86:301\u2013311.","DOI":"10.1016\/j.eururo.2024.05.014"},{"issue":"1","key":"8892_CR51","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","volume":"62","author":"J Palou","year":"2012","unstructured":"Palou J, Sylvester RJ, Faba OR, Parada R, Pe\u00f1a JA, Algaba F, Villavicencio H. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Gu\u00e9rin. Eur Urol. 2012;62(1):118\u201325.","journal-title":"Eur Urol"},{"issue":"1","key":"8892_CR52","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","volume":"158","author":"MS Cookson","year":"1997","unstructured":"Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997;158(1):62\u20137.","journal-title":"J Urol"},{"issue":"4","key":"8892_CR53","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, Kirkby E, McKiernan JM, Schuckman AK. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline: 2024 Amendment. J Urol. 2024;211(4):533\u20138.","journal-title":"J Urol"},{"key":"8892_CR54","doi-asserted-by":"publisher","first-page":"657483","DOI":"10.3389\/fonc.2021.657483","volume":"11","author":"J Zhang","year":"2021","unstructured":"Zhang J, Dai D, Tian J, Li L, Bai J, Xu Y, Wang Z, Tang A. Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer. Front Oncol. 2021;11:657483.","journal-title":"Front Oncol"},{"issue":"2","key":"8892_CR55","doi-asserted-by":"publisher","first-page":"200818","DOI":"10.1016\/j.omton.2024.200818","volume":"32","author":"MA Papadimitriou","year":"2024","unstructured":"Papadimitriou MA, Pilala KM, Panoutsopoulou K, Levis P, Kotronopoulos G, Kanaki Z, Loules G, Zamanakou M, Linardoutsos D, Sideris DC, et al. CDKN2A copy number alteration in bladder cancer: Integrative analysis in patient-derived xenografts and cancer patients. Mol Ther Oncol. 2024;32(2):200818.","journal-title":"Mol Ther Oncol"},{"issue":"10","key":"8892_CR56","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","volume":"20","author":"M Maas","year":"2023","unstructured":"Maas M, Todenh\u00f6fer T, Black PC. Urine biomarkers in bladder cancer - current status and future perspectives. Nat Rev Urol. 2023;20(10):597\u2013614.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"8892_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.euo.2022.04.008","volume":"5","author":"PJ Hensley","year":"2022","unstructured":"Hensley PJ, Panebianco V, Pietzak E, Kutikov A, Vikram R, Galsky MD, Shariat SF, Roupret M, Kamat AM. Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations. Eur Urol Oncol. 2022;5(4):403\u201311.","journal-title":"Eur Urol Oncol"},{"issue":"23","key":"8892_CR58","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","volume":"29","author":"SV Lindskrog","year":"2023","unstructured":"Lindskrog SV, Birkenkamp-Demtr\u00f6der K, Nordentoft I, Laliotis G, Lamy P, Christensen E, Renner D, Andreasen TG, Lange N, Sharma S, et al. Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up. Clin Cancer Res. 2023;29(23):4797\u2013807.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"8892_CR59","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Sethi H, Shchegrova S, Salari R, Nordentoft I, Wu HT, Knudsen M, Lamy P, Lindskrog SV, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol. 2019;37(18):1547\u201357.","journal-title":"J Clin Oncol"},{"issue":"5","key":"8892_CR60","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.euo.2024.03.002","volume":"7","author":"R Ben-David","year":"2024","unstructured":"Ben-David R, Tillu N, Cumarasamy S, Alerasool P, Rich JM, Kaufmann B, Elkun Y, Attalla K, Mehrazin R, Wiklund P, et al. Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy. Eur Urol Oncol. 2024;7(5):1105\u201312.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"8892_CR61","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.euo.2024.07.001","volume":"8","author":"JP Sfakianos","year":"2025","unstructured":"Sfakianos JP, Basu A, Laliotis G, Cumarasamy S, Rich JM, Kommalapati A, Glover M, Mahmood T, Tillu N, Hoimes CJ, et al. Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer. Eur Urol Oncol. 2025;8(2):306\u201314.","journal-title":"Eur Urol Oncol"},{"issue":"7867","key":"8892_CR62","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S, Gschwend JE, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595(7867):432\u20137.","journal-title":"Nature"},{"issue":"2","key":"8892_CR63","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","volume":"85","author":"T Powles","year":"2024","unstructured":"Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur Urol. 2024;85(2):114\u201322.","journal-title":"Eur Urol"},{"issue":"2","key":"8892_CR64","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol. 2022;82(2):212\u201322.","journal-title":"Eur Urol"},{"issue":"3","key":"8892_CR65","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41591-022-02199-y","volume":"29","author":"J van Dorp","year":"2023","unstructured":"van Dorp J, Pipinikas C, Suelmann BBM, Mehra N, van Dijk N, Marsico G, van Montfoort ML, Hackinger S, Braaf LM, Amarante T, et al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Nat Med. 2023;29(3):588\u201392.","journal-title":"Nat Med"},{"issue":"1","key":"8892_CR66","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D. Bladder cancer. Nat Rev Dis Primers. 2023;9(1):58.","journal-title":"Nat Rev Dis Primers"},{"key":"8892_CR67","doi-asserted-by":"publisher","first-page":"e2400472","DOI":"10.1200\/PO-24-00472","volume":"9","author":"T Sakatani","year":"2025","unstructured":"Sakatani T, Sumiyoshi T, Kita Y, Takada H, Nakamura K, Hamada A, Murakami K, Sano T, Goto T, Sawada A, et al. Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer. JCO Precis Oncol. 2025;9:e2400472.","journal-title":"JCO Precis Oncol"},{"issue":"24","key":"8892_CR68","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","volume":"24","author":"R Raja","year":"2018","unstructured":"Raja R, Kuziora M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA, Ranade K. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clin Cancer Res. 2018;24(24):6212\u201322.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"8892_CR69","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/1878-0261.13196","volume":"16","author":"PAJ Mendelaar","year":"2022","unstructured":"Mendelaar PAJ, Robbrecht DGJ, Rijnders M, de Wit R, de Weerd V, Deger T, Westgeest HM, Aarts MJB, Voortman J, Martens JWM, et al. Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer. Mol Oncol. 2022;16(10):2086\u201397.","journal-title":"Mol Oncol"},{"issue":"3","key":"8892_CR70","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3892\/ol.2023.13975","volume":"26","author":"K Hamada","year":"2023","unstructured":"Hamada K, Nagumo Y, Kandori S, Tanuma K, Shiga M, Hoshi A, Negoro H, Kojima T, Mathis BJ, Nishiyama H. Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma. Oncol Lett. 2023;26(3):389.","journal-title":"Oncol Lett"},{"issue":"2","key":"8892_CR71","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/path.6166","volume":"261","author":"J Zang","year":"2023","unstructured":"Zang J, Zhang R, Jin D, Xie F, Shahatiaili A, Wu G, Zhang Y, Zhao Z, Du P, Jia S, et al. Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial. J Pathol. 2023;261(2):198\u2013209.","journal-title":"J Pathol"},{"issue":"2","key":"8892_CR72","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.euo.2023.08.009","volume":"7","author":"SH Tolmeijer","year":"2024","unstructured":"Tolmeijer SH, van Wilpe S, Geerlings MJ, von Rhein D, Smilde TJ, Kloots ISH, Westdorp H, Coskunt\u00fcrk M, Oving IM, van Ipenburg JA, et al. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer. Eur Urol Oncol. 2024;7(2):282\u201391.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"8892_CR73","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","volume":"75","author":"N Sundahl","year":"2019","unstructured":"Sundahl N, Vandekerkhove G, Decaestecker K, Meireson A, De Visschere P, Fonteyne V, De Maeseneer D, Reynders D, Goetghebeur E, Van Dorpe J, et al. Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. Eur Urol. 2019;75(5):707\u201311.","journal-title":"Eur Urol"},{"issue":"1","key":"8892_CR74","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","volume":"12","author":"G Vandekerkhove","year":"2021","unstructured":"Vandekerkhove G, Lavoie JM, Annala M, Murtha AJ, Sundahl N, Walz S, Sano T, Taavitsainen S, Ritch E, Fazli L, et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun. 2021;12(1):184.","journal-title":"Nat Commun"},{"issue":"7","key":"8892_CR75","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","volume":"8","author":"SK Pal","year":"2018","unstructured":"Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, et al. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1\u20133 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Cancer Discov. 2018;8(7):812\u201321.","journal-title":"Cancer Discov"},{"key":"8892_CR76","doi-asserted-by":"publisher","first-page":"113368","DOI":"10.1016\/j.ejca.2023.113368","volume":"195","author":"C Helal","year":"2023","unstructured":"Helal C, Pobel C, Bayle A, Vasseur D, Nicotra C, Blanc-Durand F, Naoun N, Bernard-Tessier A, Patrikidou A, Colomba E, et al. Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer. Eur J Cancer. 2023;195:113368.","journal-title":"Eur J Cancer"},{"issue":"4","key":"8892_CR77","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/1078-0432.CCR-21-2136","volume":"28","author":"JK Lee","year":"2022","unstructured":"Lee JK, Hazar-Rethinam M, Decker B, Gjoerup O, Madison RW, Lieber DS, Chung JH, Schrock AB, Creeden J, Venstrom J, et al. The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. Clin Cancer Res. 2022;28(4):728\u201337.","journal-title":"Clin Cancer Res"},{"key":"8892_CR78","doi-asserted-by":"publisher","first-page":"100003","DOI":"10.1016\/j.jlb.2023.100003","volume":"1","author":"S Mishima","year":"2023","unstructured":"Mishima S, Nakamura Y, Tukachinsky H, Taniguchi H, Kadowaki S, Kato K, Oki E, Satoh T, Aoki D, Yamazaki K, et al. Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN. J Liq Biopsy. 2023;1:100003.","journal-title":"J Liq Biopsy"},{"issue":"9","key":"8892_CR79","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1038\/s41591-024-03091-7","volume":"30","author":"T Powles","year":"2024","unstructured":"Powles T, Chang YH, Yamamoto Y, Munoz J, Reyes-Cosmelli F, Peer A, Cohen G, Yu EY, Lorch A, Bavle A, et al. Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial. Nat Med. 2024;30(9):2508\u201316.","journal-title":"Nat Med"},{"issue":"10","key":"8892_CR80","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875\u201388.","journal-title":"N Engl J Med"},{"issue":"10","key":"8892_CR81","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1158\/1078-0432.CCR-23-3738","volume":"30","author":"WF Maguire","year":"2024","unstructured":"Maguire WF, Lee D, Weinstock C, Gao X, Bulik CC, Agrawal S, Chang E, Hamed SS, Bloomquist EW, Tang S, et al. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2024;30(10):2011\u20136.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8892_CR82","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","volume":"6","author":"D Lin","year":"2021","unstructured":"Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6(1):404.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"8892_CR83","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.trecan.2021.07.001","volume":"7","author":"E Schuster","year":"2021","unstructured":"Schuster E, Taftaf R, Reduzzi C, Albert MK, Romero-Calvo I, Liu H. Better together: circulating tumor cell clustering in metastatic cancer. Trends Cancer. 2021;7(11):1020\u201332.","journal-title":"Trends Cancer"},{"issue":"5","key":"8892_CR84","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","volume":"158","author":"N Aceto","year":"2014","unstructured":"Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110\u201322.","journal-title":"Cell"},{"issue":"7","key":"8892_CR85","doi-asserted-by":"publisher","first-page":"E854","DOI":"10.1073\/pnas.1508541113","volume":"113","author":"KJ Cheung","year":"2016","unstructured":"Cheung KJ, Padmanaban V, Silvestri V, Schipper K, Cohen JD, Fairchild AN, Gorin MA, Verdone JE, Pienta KJ, Bader JS, et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci U S A. 2016;113(7):E854\u2013863.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"8892_CR86","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","volume":"10","author":"WJ Allard","year":"2004","unstructured":"Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897\u2013904.","journal-title":"Clin Cancer Res"},{"key":"8892_CR87","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cobme.2017.08.001","volume":"3","author":"SH Au","year":"2017","unstructured":"Au SH, Edd J, Haber DA, Maheswaran S, Stott SL, Toner M. Clusters of Circulating Tumor Cells: a Biophysical and Technological Perspective. Curr Opin Biomed Eng. 2017;3:13\u20139.","journal-title":"Curr Opin Biomed Eng"},{"issue":"1","key":"8892_CR88","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12943-023-01880-1","volume":"22","author":"NH Stoecklein","year":"2023","unstructured":"Stoecklein NH, Fluegen G, Guglielmi R, Neves RPL, Hackert T, Birgin E, Cieslik SA, Sudarsanam M, Driemel C, van Dalum G, et al. Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis. Mol Cancer. 2023;22(1):181.","journal-title":"Mol Cancer"},{"issue":"7","key":"8892_CR89","doi-asserted-by":"publisher","first-page":"E219","DOI":"10.1002\/dc.25141","volume":"51","author":"M Jahan","year":"2023","unstructured":"Jahan M, Mittal A, Rao S, Kishore S, Singh A, Jadli M, Paul P, Iqbal A, Chowdhury N. Cytomorphologic visualization of circulating tumor cells in urinary bladder cancer patients using ScreenCell\u2122 technology: Potential as a simple cytology test. Diagn Cytopathol. 2023;51(7):E219\u201323.","journal-title":"Diagn Cytopathol"},{"issue":"3","key":"8892_CR90","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1442-2042.2010.02454.x","volume":"17","author":"T Okegawa","year":"2010","unstructured":"Okegawa T, Hayashi K, Hara H, Nutahara K, Higashihara E. Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int J Urol. 2010;17(3):254\u20138.","journal-title":"Int J Urol"},{"issue":"1","key":"8892_CR91","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.juro.2014.06.083","volume":"193","author":"H Engilbertsson","year":"2015","unstructured":"Engilbertsson H, Aaltonen KE, Bj\u00f6rnsson S, Kristmundsson T, Patschan O, Ryd\u00e9n L, Gudjonsson S. Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J Urol. 2015;193(1):53\u20137.","journal-title":"J Urol"},{"issue":"4","key":"8892_CR92","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabi\u00e8res","year":"2021","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021;11(4):858\u201373.","journal-title":"Cancer Discov"},{"issue":"1","key":"8892_CR93","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/1878-0261.12802","volume":"15","author":"PAJ Mendelaar","year":"2021","unstructured":"Mendelaar PAJ, Kraan J, Van M, Zeune LL, Terstappen L, Oomen-de Hoop E, Martens JWM, Sleijfer S. Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients. Mol Oncol. 2021;15(1):116\u201325.","journal-title":"Mol Oncol"},{"issue":"6","key":"8892_CR94","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/ijc.20366","volume":"111","author":"I Osman","year":"2004","unstructured":"Osman I, Kang M, Lee A, Deng FM, Polsky D, Mikhail M, Chang C, David DA, Mitra N, Wu XR, et al. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients. Int J Cancer. 2004;111(6):934\u20139.","journal-title":"Int J Cancer"},{"issue":"7","key":"8892_CR95","doi-asserted-by":"publisher","first-page":"7217","DOI":"10.1007\/s13277-014-1894-0","volume":"35","author":"F Qi","year":"2014","unstructured":"Qi F, Liu Y, Zhao R, Zou X, Zhang L, Li J, Wang Y, Li F, Zou X, Xia Y, et al. Quantitation of rare circulating tumor cells by folate receptor \u03b1 ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance. Tumour Biol. 2014;35(7):7217\u201323.","journal-title":"Tumour Biol"},{"issue":"3","key":"8892_CR96","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.juro.2015.02.2951","volume":"194","author":"A Alva","year":"2015","unstructured":"Alva A, Friedlander T, Clark M, Huebner T, Daignault S, Hussain M, Lee C, Hafez K, Hollenbeck B, Weizer A, et al. Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. J Urol. 2015;194(3):790\u20138.","journal-title":"J Urol"},{"issue":"2","key":"8892_CR97","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/CU9.0000000000000091","volume":"16","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi M, Abe H, Arai K, Murakami S, Kamai T. Circulating tumor cells and cell-free tumor DNA analyses in urothelial cancer using the LiquidBiopsy platform. Curr Urol. 2022;16(2):99\u2013106.","journal-title":"Curr Urol"},{"issue":"10","key":"8892_CR98","doi-asserted-by":"publisher","first-page":"e606609","DOI":"10.1016\/j.urolonc.2017.05.021","volume":"35","author":"J Abrahamsson","year":"2017","unstructured":"Abrahamsson J, Aaltonen K, Engilbertsson H, Liedberg F, Patschan O, Ryd\u00e9n L, Sj\u00f6dahl G, Gudjonsson S. Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival. Urol Oncol. 2017;35(10):e606609\u201316.","journal-title":"Urol Oncol"},{"issue":"17","key":"8892_CR99","doi-asserted-by":"publisher","first-page":"24677","DOI":"10.18632\/oncotarget.8250","volume":"7","author":"KA Hyun","year":"2016","unstructured":"Hyun KA, Koo GB, Han H, Sohn J, Choi W, Kim SI, Jung HI, Kim YS. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget. 2016;7(17):24677\u201387.","journal-title":"Oncotarget"},{"issue":"4","key":"8892_CR100","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.urology.2011.05.045","volume":"78","author":"TW Flaig","year":"2011","unstructured":"Flaig TW, Wilson S, van Bokhoven A, Varella-Garcia M, Wolfe P, Maroni P, Genova EE, Morales D, Lucia MS. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology. 2011;78(4):863\u20137.","journal-title":"Urology"},{"issue":"14","key":"8892_CR101","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1021\/acs.analchem.3c05749","volume":"96","author":"Z Wang","year":"2024","unstructured":"Wang Z, Chen X, Qiu X, Chen Y, Wang T, Lv L, Guo X, Yang F, Tang M, Gu W, et al. High-Fidelity Sensitive Tracing Circulating Tumor Cell Telomerase Activity. Anal Chem. 2024;96(14):5527\u201336.","journal-title":"Anal Chem"},{"issue":"1","key":"8892_CR102","first-page":"502","volume":"15","author":"L Wang","year":"2023","unstructured":"Wang L, Ding D. Correlation between mesenchymal circulating tumor cells and prognosis of urologic malignancies: a single-center retrospective analysis. Am J Transl Res. 2023;15(1):502\u201310.","journal-title":"Am J Transl Res"},{"key":"8892_CR103","doi-asserted-by":"publisher","first-page":"101036","DOI":"10.1016\/j.neo.2024.101036","volume":"57","author":"Z Niu","year":"2024","unstructured":"Niu Z, Kozminsky M, Day KC, Broses LJ, Henderson ML, Patsalis C, Tagett R, Qin Z, Blumberg S, Reichert ZR, et al. Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics. Neoplasia. 2024;57:101036.","journal-title":"Neoplasia"},{"issue":"1","key":"8892_CR104","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1186\/s12885-020-07684-6","volume":"20","author":"TM Kim","year":"2020","unstructured":"Kim TM, Yoo JS, Moon HW, Hur KJ, Choi JB, Hong SH, Lee JY, Ha US. Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-up. BMC Cancer. 2020;20(1):1203.","journal-title":"BMC Cancer"},{"issue":"7800","key":"8892_CR105","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1038\/d41586-020-00844-5","volume":"579","author":"C Alix-Panabi\u00e8res","year":"2020","unstructured":"Alix-Panabi\u00e8res C. The future of liquid biopsy. Nature. 2020;579(7800):S9.","journal-title":"Nature"},{"issue":"1","key":"8892_CR106","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41416-023-02491-9","volume":"130","author":"SZ Eslami","year":"2024","unstructured":"Eslami SZ, Cort\u00e9s-Hern\u00e1ndez LE, Sinoquet L, Gauthier L, Vautrot V, Cayrefourcq L, Avoscan L, Jacot W, Pouderoux S, Viala M, et al. Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer. Br J Cancer. 2024;130(1):63\u201372.","journal-title":"Br J Cancer"},{"issue":"6378","key":"8892_CR107","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926\u201330.","journal-title":"Science"},{"key":"8892_CR108","doi-asserted-by":"crossref","unstructured":"Buscail E, Alix-Panabi\u00e8res C, Quincy P, Cauvin T, Chauvet A, Degrandi O, Caumont C, Verdon S, Lamrissi I, Moranvillier I, et al. High clinical value of liquid biopsy to detect circulating tumor cells and tumor exosomes in pancreatic ductal adenocarcinoma patients eligible for up-front surgery. Cancers (Basel). 2019;11(11):1656.","DOI":"10.3390\/cancers11111656"},{"issue":"10","key":"8892_CR109","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/j.1464-410X.2010.09562.x","volume":"107","author":"M Rink","year":"2011","unstructured":"Rink M, Chun FK, Minner S, Friedrich M, Mauermann O, Heinzer H, Huland H, Fisch M, Pantel K, Riethdorf S. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int. 2011;107(10):1668\u201375.","journal-title":"BJU Int"},{"issue":"2","key":"8892_CR110","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ijc.30445","volume":"140","author":"A Soave","year":"2017","unstructured":"Soave A, Riethdorf S, Dahlem R, von Amsberg G, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M. A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. Int J Cancer. 2017;140(2):381\u20139.","journal-title":"Int J Cancer"},{"issue":"4","key":"8892_CR111","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.eururo.2012.01.017","volume":"61","author":"M Rink","year":"2012","unstructured":"Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth LA, Ahyai SA, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol. 2012;61(4):810\u20137.","journal-title":"Eur Urol"},{"issue":"6","key":"8892_CR112","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bju.13782","volume":"119","author":"A Soave","year":"2017","unstructured":"Soave A, Riethdorf S, Dahlem R, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M. Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy. BJU Int. 2017;119(6):854\u201361.","journal-title":"BJU Int"},{"issue":"35","key":"8892_CR113","doi-asserted-by":"publisher","first-page":"59527","DOI":"10.18632\/oncotarget.18521","volume":"8","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Fan W, Deng Q, Tang S, Wang P, Xu P, Wang J, Yu M. The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies. Oncotarget. 2017;8(35):59527\u201338.","journal-title":"Oncotarget"},{"issue":"4","key":"8892_CR114","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1016\/j.clgc.2017.01.011","volume":"15","author":"GM Busetto","year":"2017","unstructured":"Busetto GM, Ferro M, Del Giudice F, Antonini G, Chung BI, Sperduti I, Giannarelli D, Lucarelli G, Borghesi M, Musi G, et al. The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2017;15(4):e661\u20136.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"8892_CR115","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/j.1464-410X.2009.09130.x","volume":"106","author":"A Gradilone","year":"2010","unstructured":"Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E, Naso G, Vincenzi B, Cristini C, De Berardinis E, Di Silverio F, et al. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int. 2010;106(5):710\u20135.","journal-title":"BJU Int"},{"issue":"9","key":"8892_CR116","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1093\/annonc\/mdr619","volume":"23","author":"P Gazzaniga","year":"2012","unstructured":"Gazzaniga P, Gradilone A, de Berardinis E, Busetto GM, Raimondi C, Gandini O, Nicolazzo C, Petracca A, Vincenzi B, Farcomeni A, et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. Ann Oncol. 2012;23(9):2352\u20136.","journal-title":"Ann Oncol"},{"issue":"8","key":"8892_CR117","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1002\/ijc.28830","volume":"135","author":"P Gazzaniga","year":"2014","unstructured":"Gazzaniga P, de Berardinis E, Raimondi C, Gradilone A, Busetto GM, De Falco E, Nicolazzo C, Giovannone R, Gentile V, Cortesi E, et al. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int J Cancer. 2014;135(8):1978\u201382.","journal-title":"Int J Cancer"},{"issue":"10","key":"8892_CR118","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00432-017-2449-8","volume":"143","author":"C Nicolazzo","year":"2017","unstructured":"Nicolazzo C, Busetto GM, Del Giudice F, Sperduti I, Giannarelli D, Gradilone A, Gazzaniga P, de Berardinis E, Raimondi C. The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). J Cancer Res Clin Oncol. 2017;143(10):1971\u20136.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"8892_CR119","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1634\/theoncologist.2018-0784","volume":"24","author":"C Nicolazzo","year":"2019","unstructured":"Nicolazzo C, Busetto GM, Gradilone A, Sperduti I, Del Giudice F, Loreni F, Cortesi E, de Berardinis E, Gazzaniga P, Raimondi C. Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial. Oncologist. 2019;24(5):612\u20136.","journal-title":"Oncologist"},{"issue":"3","key":"8892_CR120","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s13402-023-00785-x","volume":"46","author":"D Jin","year":"2023","unstructured":"Jin D, Qian L, Xia J, Zhang R, Yang G, Zhang L, Xue W, Cao M, Dong L, Chen H. In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy. Cell Oncol (Dordr). 2023;46(3):793\u20137.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"8892_CR121","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.euo.2020.09.003","volume":"4","author":"C Nicolazzo","year":"2021","unstructured":"Nicolazzo C, de Berardinis E, Gazzaniga P. Liquid Biopsy for Predicting Bacillus Calmette-Gu\u00e9rin Unresponsiveness in Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2021;4(1):124\u20135.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"8892_CR122","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12032-023-01977-z","volume":"40","author":"D Jin","year":"2023","unstructured":"Jin D, Qian L, Xia J, Zhang R, Yang G, Zhang L, Xue W, Cao M, Dong L, Chen H. In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer. Med Oncol. 2023;40(4):113.","journal-title":"Med Oncol"},{"issue":"7","key":"8892_CR123","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/intimm\/dxh267","volume":"17","author":"MP Caby","year":"2005","unstructured":"Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. Exosomal-like vesicles are present in human blood plasma. Int Immunol. 2005;17(7):879\u201387.","journal-title":"Int Immunol"},{"key":"8892_CR124","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1479-5876-9-9","volume":"9","author":"C L\u00e4sser","year":"2011","unstructured":"L\u00e4sser C, Alikhani VS, Ekstr\u00f6m K, Eldh M, Paredes PT, Bossios A, Sj\u00f6strand M, Gabrielsson S, L\u00f6tvall J, Valadi H. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl Med. 2011;9:9.","journal-title":"J Transl Med"},{"key":"8892_CR125","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","volume":"30","author":"M Colombo","year":"2014","unstructured":"Colombo M, Raposo G, Th\u00e9ry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255\u201389.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"8","key":"8892_CR126","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nri2567","volume":"9","author":"C Th\u00e9ry","year":"2009","unstructured":"Th\u00e9ry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9(8):581\u201393.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"8892_CR127","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","volume":"21","author":"M Mathieu","year":"2019","unstructured":"Mathieu M, Martin-Jaular L, Lavieu G, Th\u00e9ry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9\u201317.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"8892_CR128","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb1596","volume":"9","author":"H Valadi","year":"2007","unstructured":"Valadi H, Ekstr\u00f6m K, Bossios A, Sj\u00f6strand M, Lee JJ, L\u00f6tvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654\u20139.","journal-title":"Nat Cell Biol"},{"issue":"3\u20134","key":"8892_CR129","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/prca.201400114","volume":"9","author":"S Boukouris","year":"2015","unstructured":"Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteom Clin Appl. 2015;9(3\u20134):358\u201367.","journal-title":"Proteom Clin Appl"},{"issue":"10","key":"8892_CR130","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/sj.bjc.6605058","volume":"100","author":"J Nilsson","year":"2009","unstructured":"Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer. 2009;100(10):1603\u20137.","journal-title":"Br J Cancer"},{"issue":"15","key":"8892_CR131","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.7150\/jca.25201","volume":"9","author":"S Li","year":"2018","unstructured":"Li S, Zhao Y, Chen W, Yin L, Zhu J, Zhang H, Cai C, Li P, Huang L, Ma P. Exosomal ephrinA2 derived from serum as a potential biomarker for prostate cancer. J Cancer. 2018;9(15):2659\u201365.","journal-title":"J Cancer"},{"issue":"18","key":"8892_CR132","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1002\/cam4.4168","volume":"10","author":"S Zhu","year":"2021","unstructured":"Zhu S, Ni Y, Sun G, Wang Z, Chen J, Zhang X, Zhao J, Zhu X, Dai J, Liu Z, et al. Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abiraterone. Cancer Med. 2021;10(18):6282\u201390.","journal-title":"Cancer Med"},{"issue":"11","key":"8892_CR133","doi-asserted-by":"publisher","first-page":"11075","DOI":"10.1021\/acsnano.5b04527","volume":"9","author":"GK Joshi","year":"2015","unstructured":"Joshi GK, Deitz-McElyea S, Liyanage T, Lawrence K, Mali S, Sardar R, Korc M. Label-Free Nanoplasmonic-Based Short Noncoding RNA Sensing at Attomolar Concentrations Allows for Quantitative and Highly Specific Assay of MicroRNA-10b in Biological Fluids and Circulating Exosomes. ACS Nano. 2015;9(11):11075\u201389.","journal-title":"ACS Nano"},{"issue":"4","key":"8892_CR134","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1021\/acsnano.7b08199","volume":"12","author":"JM Lewis","year":"2018","unstructured":"Lewis JM, Vyas AD, Qiu Y, Messer KS, White R, Heller MJ. Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood. ACS Nano. 2018;12(4):3311\u201320.","journal-title":"ACS Nano"},{"key":"8892_CR135","doi-asserted-by":"crossref","unstructured":"Droste M, Tertel T, Jeruschke S, Dittrich R, Kontopoulou E, Walkenfort B, B\u00f6rger V, Hoyer PF, B\u00fcscher AK, Thakur BK, et al. Single extracellular vesicle analysis performed by imaging flow cytometry and nanoparticle tracking analysis evaluate the accuracy of urinary extracellular vesicle preparation techniques differently. Int J Mol Sci. 2021;22(22).","DOI":"10.3390\/ijms222212436"},{"issue":"4","key":"8892_CR136","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2021.01.074","volume":"32","author":"W Yu","year":"2021","unstructured":"Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, Breakefield XO, Skog JK. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32(4):466\u201377.","journal-title":"Ann Oncol"},{"issue":"12","key":"8892_CR137","doi-asserted-by":"publisher","first-page":"e32621","DOI":"10.1016\/j.heliyon.2024.e32621","volume":"10","author":"J Liu","year":"2024","unstructured":"Liu J, Zhijin Z, Zhang W, Niraj M, Yang F, Changcheng G, Shen L, Xu T, Liu S, Junfeng Z, et al. Urinary exosomes: Potential diagnostic markers and application in bladder cancer. Heliyon. 2024;10(12):e32621.","journal-title":"Heliyon"},{"issue":"1","key":"8892_CR138","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12964-021-00768-1","volume":"19","author":"Z Jiang","year":"2021","unstructured":"Jiang Z, Zhang Y, Zhang Y, Jia Z, Zhang Z, Yang J. Cancer derived exosomes induce macrophages immunosuppressive polarization to promote bladder cancer progression. Cell Commun Signal. 2021;19(1):93.","journal-title":"Cell Commun Signal"},{"key":"8892_CR139","doi-asserted-by":"crossref","unstructured":"Huyan T, Gao L, Gao N, Wang C, Guo W, Zhou X, Li Q. miR-221-5p and miR-186-5p are the critical bladder cancer derived Exosomal miRNAs in natural killer cell dysfunction. Int J Mol Sci. 2022;23(23):15177.","DOI":"10.3390\/ijms232315177"},{"issue":"10","key":"8892_CR140","first-page":"6277","volume":"12","author":"L Yan","year":"2020","unstructured":"Yan L, Li Q, Sun K, Jiang F. MiR-4644 is upregulated in plasma exosomes of bladder cancer patients and promotes bladder cancer progression by targeting UBIAD1. Am J Transl Res. 2020;12(10):6277\u201389.","journal-title":"Am J Transl Res"},{"issue":"4","key":"8892_CR141","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/cbin.11292","volume":"44","author":"X Yin","year":"2020","unstructured":"Yin X, Zheng X, Liu M, Wang D, Sun H, Qiu Y, Chen J, Shi B. Exosomal miR-663b targets Ets2-repressor factor to promote proliferation and the epithelial-mesenchymal transition of bladder cancer cells. Cell Biol Int. 2020;44(4):958\u201365.","journal-title":"Cell Biol Int"},{"key":"8892_CR142","doi-asserted-by":"crossref","unstructured":"You X, Wang Y, Meng J, Han S, Liu L, Sun Y, Zhang J, Sun S, Li X, Sun W, et al. Exosomal miR\u2013663b exposed to TGF\u2013\u03b21 promotes cervical cancer metastasis and epithelial\u2013mesenchymal transition by targeting MGAT3. Oncol Rep. 2021;45(4):12.","DOI":"10.3892\/or.2021.7963"},{"issue":"1","key":"8892_CR143","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s13402-020-00500-0","volume":"44","author":"G Shan","year":"2021","unstructured":"Shan G, Zhou X, Gu J, Zhou D, Cheng W, Wu H, Wang Y, Tang T, Wang X. Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt\/\u03b2-catenin pathway and upregulating PTEN. Cell Oncol (Dordr). 2021;44(1):45\u201359.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"8892_CR144","doi-asserted-by":"publisher","first-page":"2290033","DOI":"10.1080\/15384047.2023.2290033","volume":"25","author":"Z Liu","year":"2024","unstructured":"Liu Z, Du D, Zhang S. Tumor-derived exosomal miR-1247-3p promotes angiogenesis in bladder cancer by targeting FOXO1. Cancer Biol Ther. 2024;25(1):2290033.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"8892_CR145","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.clgc.2024.01.012","volume":"22","author":"H Yuan","year":"2024","unstructured":"Yuan H, Wang T, Peng P, Xu Z, Feng F, Cui Y, Ma J, Wu J. Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment. Clin Genitourin Cancer. 2024;22(2):569\u2013e579561.","journal-title":"Clin Genitourin Cancer"},{"key":"8892_CR146","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3389\/fonc.2019.00729","volume":"9","author":"XH Yin","year":"2019","unstructured":"Yin XH, Jin YH, Cao Y, Wong Y, Weng H, Sun C, Deng JH, Zeng XT. Development of a 21-miRNA Signature Associated With the Prognosis of Patients With Bladder Cancer. Front Oncol. 2019;9:729.","journal-title":"Front Oncol"},{"key":"8892_CR147","doi-asserted-by":"publisher","first-page":"1482765","DOI":"10.3389\/fimmu.2024.1482765","volume":"15","author":"J Zou","year":"2024","unstructured":"Zou J, Xu B, Luo P, Chen T, Duan H. Non-coding RNAs in bladder cancer, a bridge between gut microbiota and host? Front Immunol. 2024;15:1482765.","journal-title":"Front Immunol"},{"issue":"2","key":"8892_CR148","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.juro.2014.02.035","volume":"192","author":"CJ Beckham","year":"2014","unstructured":"Beckham CJ, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen FK, Scosyrev E, Messing EM, Lee YF. Bladder cancer exosomes contain EDIL-3\/Del1 and facilitate cancer progression. J Urol. 2014;192(2):583\u201392.","journal-title":"J Urol"},{"issue":"1","key":"8892_CR149","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12967-022-03508-2","volume":"20","author":"Q Song","year":"2022","unstructured":"Song Q, Yu H, Cheng Y, Han J, Li K, Zhuang J, Lv Q, Yang X, Yang H. Bladder cancer-derived exosomal KRT6B promotes invasion and metastasis by inducing EMT and regulating the immune microenvironment. J Transl Med. 2022;20(1):308.","journal-title":"J Transl Med"},{"issue":"3","key":"8892_CR150","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/cbf.3462","volume":"38","author":"L Yan","year":"2020","unstructured":"Yan L, Wang P, Fang W, Liang C. Cancer-associated fibroblasts-derived exosomes-mediated transfer of LINC00355 regulates bladder cancer cell proliferation and invasion. Cell Biochem Funct. 2020;38(3):257\u201365.","journal-title":"Cell Biochem Funct"},{"issue":"6","key":"8892_CR151","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/abbs\/gmab041","volume":"53","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Luo G, You S, Zhang L, Liang C, Chen X. Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder cancer cell proliferation and invasion by regulating miR-15a-5p\/HMGA2 axis. Acta Biochim Biophys Sin (Shanghai). 2021;53(6):673\u201382.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"8892_CR152","doi-asserted-by":"crossref","unstructured":"Huang CS, Ho JY, Chiang JH, Yu CP, Yu DS. Exosome-derived LINC00960 and LINC02470 promote the epithelial-mesenchymal transition and aggressiveness of bladder cancer cells. Cells. 2020;9(6):1419.","DOI":"10.3390\/cells9061419"},{"issue":"7","key":"8892_CR153","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/cbin.11590","volume":"45","author":"H Yang","year":"2021","unstructured":"Yang H, Qu H, Huang H, Mu Z, Mao M, Xie Q, Wang K, Hu B. Exosomes-mediated transfer of long noncoding RNA LINC01133 represses bladder cancer progression via regulating the Wnt signaling pathway. Cell Biol Int. 2021;45(7):1510\u201322.","journal-title":"Cell Biol Int"},{"issue":"30","key":"8892_CR154","doi-asserted-by":"publisher","first-page":"e2202993","DOI":"10.1002\/advs.202202993","volume":"9","author":"X Li","year":"2022","unstructured":"Li X, Peng X, Zhang C, Bai X, Li Y, Chen G, Guo H, He W, Zhou X, Gou X. Bladder Cancer-Derived Small Extracellular Vesicles Promote Tumor Angiogenesis by Inducing HBP-Related Metabolic Reprogramming and SerRS O-GlcNAcylation in Endothelial Cells. Adv Sci (Weinh). 2022;9(30):e2202993.","journal-title":"Adv Sci (Weinh)"},{"key":"8892_CR155","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.jlb.2023.100126","volume":"2","author":"OA Bamodu","year":"2023","unstructured":"Bamodu OA, Chung CC, Pisanic TR. 2nd: Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine. J Liq Biopsy. 2023;2:100126.","journal-title":"J Liq Biopsy"},{"key":"8892_CR156","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.2147\/OTT.S101067","volume":"9","author":"Y Cheng","year":"2016","unstructured":"Cheng Y, Zhang X, Li P, Yang C, Tang J, Deng X, Yang X, Tao J, Lu Q, Li P. MiR-200c promotes bladder cancer cell migration and invasion by directly targeting RECK. Onco Targets Ther. 2016;9:5091\u20139.","journal-title":"Onco Targets Ther"},{"key":"8892_CR157","doi-asserted-by":"crossref","unstructured":"Grimaldi AM, Lapucci C, Salvatore M, Incoronato M, Ferrari M. Urinary miRNAs as a diagnostic tool for bladder cancer: a systematic review. Biomedicines. 2022;10(11):2766.","DOI":"10.3390\/biomedicines10112766"},{"issue":"1","key":"8892_CR158","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1186\/s12885-021-08926-x","volume":"21","author":"H Lin","year":"2021","unstructured":"Lin H, Shi X, Li H, Hui J, Liu R, Chen Z, Lu Y, Tan W. Urinary Exosomal miRNAs as biomarkers of bladder Cancer and experimental verification of mechanism of miR-93-5p in bladder Cancer. BMC Cancer. 2021;21(1):1293.","journal-title":"BMC Cancer"},{"issue":"34","key":"8892_CR159","doi-asserted-by":"publisher","first-page":"55231","DOI":"10.18632\/oncotarget.10485","volume":"7","author":"D Huo","year":"2016","unstructured":"Huo D, Clayton WM, Yoshimatsu TF, Chen J, Olopade OI. Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. 2016;7(34):55231\u201348.","journal-title":"Oncotarget"},{"issue":"3","key":"8892_CR160","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.18632\/oncotarget.6487","volume":"7","author":"X Zhang","year":"2016","unstructured":"Zhang X, Zhang Y, Liu X, Fang A, Wang J, Yang Y, Wang L, Du L, Wang C. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer. Oncotarget. 2016;7(3):3255\u201366.","journal-title":"Oncotarget"},{"issue":"1","key":"8892_CR161","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"8892_CR162","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1021\/pr3008732","volume":"11","author":"CL Chen","year":"2012","unstructured":"Chen CL, Lai YF, Tang P, Chien KY, Yu JS, Tsai CH, Chen HW, Wu CC, Chung T, Hsu CW, et al. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res. 2012;11(12):5611\u201329.","journal-title":"J Proteome Res"},{"key":"8892_CR163","doi-asserted-by":"publisher","first-page":"34446","DOI":"10.1038\/srep34446","volume":"6","author":"SY Lin","year":"2016","unstructured":"Lin SY, Chang CH, Wu HC, Lin CC, Chang KP, Yang CR, Huang CP, Hsu WH, Chang CT, Chen CJ. Proteome Profiling of Urinary Exosomes Identifies Alpha 1-Antitrypsin and H2B1K as Diagnostic and Prognostic Biomarkers for Urothelial Carcinoma. Sci Rep. 2016;6:34446.","journal-title":"Sci Rep"},{"issue":"1","key":"8892_CR164","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12943-018-0893-y","volume":"17","author":"Y Zhan","year":"2018","unstructured":"Zhan Y, Du L, Wang L, Jiang X, Zhang S, Li J, Yan K, Duan W, Zhao Y, Wang L, et al. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. Mol Cancer. 2018;17(1):142.","journal-title":"Mol Cancer"},{"issue":"1","key":"8892_CR165","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/cancers6010179","volume":"6","author":"A Perez","year":"2014","unstructured":"Perez A, Loizaga A, Arceo R, Lacasa I, Rabade A, Zorroza K, Mosen-Ansorena D, Gonzalez E, Aransay AM, Falcon-Perez JM, et al. A Pilot Study on the Potential of RNA-Associated to Urinary Vesicles as a Suitable Non-Invasive Source for Diagnostic Purposes in Bladder Cancer. Cancers (Basel). 2014;6(1):179\u201392.","journal-title":"Cancers (Basel)"},{"key":"8892_CR166","doi-asserted-by":"publisher","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","volume":"115","author":"CM Ascione","year":"2023","unstructured":"Ascione CM, Napolitano F, Esposito D, Servetto A, Belli S, Santaniello A, Scagliarini S, Crocetto F, Bianco R, Formisano L. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges. Cancer Treat Rev. 2023;115:102530.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"8892_CR167","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.canlet.2008.01.038","volume":"264","author":"J Ellinger","year":"2008","unstructured":"Ellinger J, Bastian PJ, Ellinger N, Kahl P, Perabo FG, B\u00fcttner R, M\u00fcller SC, Ruecker A. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. Cancer Lett. 2008;264(2):274\u201380.","journal-title":"Cancer Lett"},{"key":"8892_CR168","doi-asserted-by":"publisher","first-page":"763790","DOI":"10.3389\/fonc.2021.763790","volume":"11","author":"Y Peng","year":"2021","unstructured":"Peng Y, Mei W, Ma K, Zeng C. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives. Front Oncol. 2021;11:763790.","journal-title":"Front Oncol"},{"issue":"3","key":"8892_CR169","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/jjco\/hyv165","volume":"46","author":"S Ikushima","year":"2016","unstructured":"Ikushima S, Ono R, Fukuda K, Sakayori M, Awano N, Kondo K. Trousseau\u2019s syndrome: cancer-associated thrombosis. Jpn J Clin Oncol. 2016;46(3):204\u20138.","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"8892_CR170","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1055\/s-0039-1688495","volume":"45","author":"HC Kwaan","year":"2019","unstructured":"Kwaan HC, Lindholm PF. Fibrin and Fibrinolysis in Cancer. Semin Thromb Hemost. 2019;45(4):413\u201322.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"8892_CR171","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40364-025-00742-w","volume":"13","author":"M Morales-Pacheco","year":"2025","unstructured":"Morales-Pacheco M, Valenzuela-Mayen M, Gonzalez-Alatriste AM, Mendoza-Almanza G, Cort\u00e9s-Ram\u00edrez SA, Losada-Garc\u00eda A, Rodr\u00edguez-Mart\u00ednez G, Gonz\u00e1lez-Ram\u00edrez I, Maldonado-Lagunas V, Vazquez-Santillan K, et al. The role of platelets in cancer: from their influence on tumor progression to their potential use in liquid biopsy. Biomark Res. 2025;13(1):27.","journal-title":"Biomark Res"},{"issue":"1","key":"8892_CR172","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1073\/pnas.61.1.46","volume":"61","author":"GJ Gasic","year":"1968","unstructured":"Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 1968;61(1):46\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8892_CR173","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/archinte.1964.03860100079008","volume":"114","author":"J Levin","year":"1964","unstructured":"Levin J, Conley CL. THROMBOCYTOSIS ASSOCIATED WITH MALIGNANT DISEASE. Arch Intern Med. 1964;114:497\u2013500.","journal-title":"Arch Intern Med"},{"issue":"659","key":"8892_CR174","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.3399\/bjgp17X691109","volume":"67","author":"SE Bailey","year":"2017","unstructured":"Bailey SE, Ukoumunne OC, Shephard EA, Hamilton W. Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. Br J Gen Pract. 2017;67(659):e405\u201313.","journal-title":"Br J Gen Pract"},{"issue":"698","key":"8892_CR175","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.3399\/bjgp20X710957","volume":"70","author":"LT Mounce","year":"2020","unstructured":"Mounce LT, Hamilton W, Bailey SE. Cancer incidence following a high-normal platelet count: cohort study using electronic healthcare records from English primary care. Br J Gen Pract. 2020;70(698):e622\u20138.","journal-title":"Br J Gen Pract"},{"issue":"1","key":"8892_CR176","doi-asserted-by":"publisher","first-page":"e2141633","DOI":"10.1001\/jamanetworkopen.2021.41633","volume":"5","author":"V Giannakeas","year":"2022","unstructured":"Giannakeas V, Kotsopoulos J, Cheung MC, Rosella L, Brooks JD, Lipscombe L, Akbari MR, Austin PC, Narod SA. Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year Period. JAMA Netw Open. 2022;5(1):e2141633.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"8892_CR177","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.3892\/ol.2017.6054","volume":"13","author":"X Zhang","year":"2017","unstructured":"Zhang X, Lv Z, Yu H, Zhu J. The clinicopathological and prognostic role of thrombocytosis in patients with cancer: A meta-analysis. Oncol Lett. 2017;13(6):5002\u20138.","journal-title":"Oncol Lett"},{"issue":"7","key":"8892_CR178","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1110352","volume":"366","author":"RL Stone","year":"2012","unstructured":"Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610\u20138.","journal-title":"N Engl J Med"},{"issue":"22","key":"8892_CR179","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1182\/blood-2009-09-242065","volume":"115","author":"A Zaslavsky","year":"2010","unstructured":"Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J, Folkman J, Italiano JE Jr., Ryeom S. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood. 2010;115(22):4605\u201313.","journal-title":"Blood"},{"issue":"2","key":"8892_CR180","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4103\/jomfp.JOMFP_174_16","volume":"22","author":"SD Mishra","year":"2018","unstructured":"Mishra SD, Bhavthankar JD, Barpande SR, Mandale MS, Humbe J. The postoperative fall in platelet count in cancer: Mirroring the catastrophe? J Oral Maxillofac Pathol. 2018;22(2):168\u201372.","journal-title":"J Oral Maxillofac Pathol"},{"issue":"14","key":"8892_CR181","first-page":"1146","volume":"135","author":"E Mammadova-Bach","year":"2020","unstructured":"Mammadova-Bach E, Gil-Pulido J, Sarukhanyan E, Burkard P, Shityakov S, Schonhart C, Stegner D, Remer K, Nurden P, Nurden AT, et al. Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived galectin-3. Blood. 2020;135(14):1146\u201360.","journal-title":"Blood"},{"issue":"14","key":"8892_CR182","doi-asserted-by":"publisher","first-page":"e88245","DOI":"10.1172\/jci.insight.88245","volume":"1","author":"E Mammadova-Bach","year":"2016","unstructured":"Mammadova-Bach E, Zigrino P, Brucker C, Bourdon C, Freund M, De Arcangelis A, Abrams SI, Orend G, Gachet C, Mangin PH. Platelet integrin \u03b16\u03b21 controls lung metastasis through direct binding to cancer cell-derived ADAM9. JCI Insight. 2016;1(14):e88245.","journal-title":"JCI Insight"},{"issue":"10","key":"8892_CR183","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1182\/blood.V96.10.3302","volume":"96","author":"JS Palumbo","year":"2000","unstructured":"Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302\u20139.","journal-title":"Blood"},{"key":"8892_CR184","doi-asserted-by":"publisher","first-page":"909767","DOI":"10.3389\/fonc.2022.909767","volume":"12","author":"W Strasenburg","year":"2022","unstructured":"Strasenburg W, J\u00f3\u017awicki J, Dur\u015blewicz J, Kuffel B, Kulczyk MP, Kowalewski A, Grzanka D, Drewa T, Adamowicz J. Tumor Cell-Induced Platelet Aggregation as an Emerging Therapeutic Target for Cancer Therapy. Front Oncol. 2022;12:909767.","journal-title":"Front Oncol"},{"issue":"1","key":"8892_CR185","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12964-023-01066-8","volume":"21","author":"H Kassassir","year":"2023","unstructured":"Kassassir H, Papiewska-Paj\u0105k I, Kryczka J, Boncela J, Kowalska MA. Platelet-derived microparticles stimulate the invasiveness of colorectal cancer cells via the p38MAPK-MMP-2\/MMP-9 axis. Cell Commun Signal. 2023;21(1):51.","journal-title":"Cell Commun Signal"},{"issue":"2","key":"8892_CR186","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1055\/s-0037-1613674","volume":"1","author":"M Zar\u00e0","year":"2017","unstructured":"Zar\u00e0 M, Guidetti GF, Boselli D, Villa C, Canobbio I, Seppi C, Visconte C, Canino J, Torti M. Release of Prometastatic Platelet-Derived Microparticles Induced by Breast Cancer Cells: A Novel Positive Feedback Mechanism for Metastasis. TH Open. 2017;1(2):e155\u201363.","journal-title":"TH Open"},{"key":"8892_CR187","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.thromres.2017.09.019","volume":"159","author":"FG Gomes","year":"2017","unstructured":"Gomes FG, Sandim V, Almeida VH, Rondon AMR, Succar BB, Hottz ED, Leal AC, Ver\u00e7oza BRF, Rodrigues JCF, Bozza PT, et al. Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms. Thromb Res. 2017;159:24\u201332.","journal-title":"Thromb Res"},{"issue":"5","key":"8892_CR188","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/ijc.20657","volume":"113","author":"A Janowska-Wieczorek","year":"2005","unstructured":"Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, Ratajczak MZ. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005;113(5):752\u201360.","journal-title":"Int J Cancer"},{"issue":"3","key":"8892_CR189","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ygyno.2019.02.026","volume":"153","author":"Y Guo","year":"2019","unstructured":"Guo Y, Cui W, Pei Y, Xu D. Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-\u03b2 signaling pathway. Gynecol Oncol. 2019;153(3):639\u201350.","journal-title":"Gynecol Oncol"},{"key":"8892_CR190","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12885-015-1304-z","volume":"15","author":"R Orellana","year":"2015","unstructured":"Orellana R, Kato S, Erices R, Bravo ML, Gonzalez P, Oliva B, Cubillos S, Valdivia A, Iba\u00f1ez C, Bra\u00f1es J, et al. Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells. BMC Cancer. 2015;15:290.","journal-title":"BMC Cancer"},{"issue":"6","key":"8892_CR191","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.3892\/or.2015.3897","volume":"33","author":"Y Jia","year":"2015","unstructured":"Jia Y, Zhang S, Miao L, Wang J, Jin Z, Gu B, Duan Z, Zhao Z, Ma S, Zhang W, et al. Activation of platelet protease-activated receptor-1 induces epithelial-mesenchymal transition and chemotaxis of colon cancer cell line SW620. Oncol Rep. 2015;33(6):2681\u20138.","journal-title":"Oncol Rep"},{"issue":"18","key":"8892_CR192","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1158\/1078-0432.CCR-16-3272","volume":"23","author":"Q Hu","year":"2017","unstructured":"Hu Q, Hisamatsu T, Haemmerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong STC, Sood AK, et al. Role of Platelet-Derived Tgf\u03b21 in the Progression of Ovarian Cancer. Clin Cancer Res. 2017;23(18):5611\u201321.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"8892_CR193","doi-asserted-by":"publisher","first-page":"7822","DOI":"10.1096\/fj.201801936RRR","volume":"33","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Unnithan RVM, Hamidi A, Caja L, Saupe F, Moustakas A, Cedervall J, Olsson AK. TANK-binding kinase 1 is a mediator of platelet-induced EMT in mammary carcinoma cells. Faseb j. 2019;33(7):7822\u201332.","journal-title":"Faseb j"},{"issue":"6","key":"8892_CR194","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.4251\/wjgo.v16.i6.2742","volume":"16","author":"LJ Zhao","year":"2024","unstructured":"Zhao LJ, Wang ZY, Liu WT, Yu LL, Qi HN, Ren J, Zhang CG. Aspirin suppresses hepatocellular carcinoma progression by inhibiting platelet activity. World J Gastrointest Oncol. 2024;16(6):2742\u201356.","journal-title":"World J Gastrointest Oncol"},{"issue":"57","key":"8892_CR195","doi-asserted-by":"publisher","first-page":"97464","DOI":"10.18632\/oncotarget.22136","volume":"8","author":"M Tang","year":"2017","unstructured":"Tang M, Jiang L, Lin Y, Wu X, Wang K, He Q, Wang X, Li W. Platelet microparticle-mediated transfer of miR-939 to epithelial ovarian cancer cells promotes epithelial to mesenchymal transition. Oncotarget. 2017;8(57):97464\u201375.","journal-title":"Oncotarget"},{"issue":"15","key":"8892_CR196","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.7150\/ijbs.76162","volume":"18","author":"F Li","year":"2022","unstructured":"Li F, Xu T, Chen P, Sun R, Li C, Zhao X, Ou J, Li J, Liu T, Zeng M, et al. Platelet-derived extracellular vesicles inhibit ferroptosis and promote distant metastasis of nasopharyngeal carcinoma by upregulating ITGB3. Int J Biol Sci. 2022;18(15):5858\u201372.","journal-title":"Int J Biol Sci"},{"issue":"Suppl 2","key":"8892_CR197","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/S0049-3848(14)50025-4","volume":"133","author":"D Stegner","year":"2014","unstructured":"Stegner D, D\u00fctting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res. 2014;133(Suppl 2):S149\u2013157.","journal-title":"Thromb Res"},{"issue":"5","key":"8892_CR198","first-page":"450","volume":"27","author":"XL Lou","year":"2015","unstructured":"Lou XL, Sun J, Gong SQ, Yu XF, Gong R, Deng H. Interaction between circulating cancer cells and platelets: clinical implication. Chin J Cancer Res. 2015;27(5):450\u201360.","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"8892_CR199","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41467-017-00411-z","volume":"8","author":"M Haemmerle","year":"2017","unstructured":"Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 2017;8(1):310.","journal-title":"Nat Commun"},{"issue":"1","key":"8892_CR200","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","volume":"11","author":"M Schlesinger","year":"2018","unstructured":"Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1):125.","journal-title":"J Hematol Oncol"},{"issue":"19","key":"8892_CR201","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-09-2123","volume":"69","author":"HG Kopp","year":"2009","unstructured":"Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69(19):7775\u201383.","journal-title":"Cancer Res"},{"issue":"15","key":"8892_CR202","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1182\/blood-2011-07-368514","volume":"118","author":"B Shao","year":"2011","unstructured":"Shao B, Wahrenbrock MG, Yao L, David T, Coughlin SR, Xia L, Varki A, McEver RP. Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood. 2011;118(15):4015\u201323.","journal-title":"Blood"},{"issue":"2","key":"8892_CR203","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/blood-2015-01-624023","volume":"126","author":"J Etulain","year":"2015","unstructured":"Etulain J, Martinod K, Wong SL, Cifuni SM, Schattner M, Wagner DD. P-selectin promotes neutrophil extracellular trap formation in mice. Blood. 2015;126(2):242\u20136.","journal-title":"Blood"},{"key":"8892_CR204","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.thromres.2019.02.026","volume":"177","author":"S Asghar","year":"2019","unstructured":"Asghar S, Parvaiz F, Manzoor S. Multifaceted role of cancer educated platelets in survival of cancer cells. Thromb Res. 2019;177:42\u201350.","journal-title":"Thromb Res"},{"issue":"3","key":"8892_CR205","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ccr.2011.08.012","volume":"20","author":"Z Granot","year":"2011","unstructured":"Granot Z, Henke E, Comen EA, King TA, Norton L, Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 2011;20(3):300\u201314.","journal-title":"Cancer Cell"},{"issue":"20","key":"8892_CR206","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1182\/blood-2008-10-186585","volume":"114","author":"H L\u00e4ubli","year":"2009","unstructured":"L\u00e4ubli H, Spanaus KS, Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood. 2009;114(20):4583\u201391.","journal-title":"Blood"},{"issue":"1","key":"8892_CR207","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ccr.2013.05.008","volume":"24","author":"D Schumacher","year":"2013","unstructured":"Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013;24(1):130\u20137.","journal-title":"Cancer Cell"},{"key":"8892_CR208","doi-asserted-by":"crossref","unstructured":"Elaskalani O, Falasca M, Moran N, Berndt MC, Metharom P. The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistance. Cancers (Basel). 2017;9(10):142.","DOI":"10.3390\/cancers9100142"},{"key":"8892_CR209","doi-asserted-by":"crossref","unstructured":"Casagrande N, Borghese C, Agostini F, Durante C, Mazzucato M, Colombatti A, Aldinucci D. In ovarian cancer multicellular spheroids, platelet releasate promotes growth, expansion of ALDH\u2009+\u2009and CD133\u2009+\u2009cancer stem cells, and protection against the cytotoxic effects of cisplatin, carboplatin and paclitaxel. Int J Mol Sci. 2021;22(6):3019.","DOI":"10.3390\/ijms22063019"},{"issue":"3","key":"8892_CR210","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1158\/1078-0432.CCR-14-0870","volume":"21","author":"J Bottsford-Miller","year":"2015","unstructured":"Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, et al. Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res. 2015;21(3):602\u201310.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"8892_CR211","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1245\/s10434-014-3988-8","volume":"22","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Choi GS, Park JS, Park S, Kawai K, Watanabe T. Clinical significance of thrombocytosis before preoperative chemoradiotherapy in rectal cancer: predicting pathologic tumor response and oncologic outcome. Ann Surg Oncol. 2015;22(2):513\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"8892_CR212","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3892\/or.2016.4898","volume":"36","author":"S Ishikawa","year":"2016","unstructured":"Ishikawa S, Miyashita T, Inokuchi M, Hayashi H, Oyama K, Tajima H, Takamura H, Ninomiya I, Ahmed AK, Harman JW, et al. Platelets surrounding primary tumor cells are related to chemoresistance. Oncol Rep. 2016;36(2):787\u201394.","journal-title":"Oncol Rep"},{"issue":"1","key":"8892_CR213","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12885-017-3279-4","volume":"17","author":"H Saito","year":"2017","unstructured":"Saito H, Fushida S, Miyashita T, Oyama K, Yamaguchi T, Tsukada T, Kinoshita J, Tajima H, Ninomiya I, Ohta T. Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study. BMC Cancer. 2017;17(1):294.","journal-title":"BMC Cancer"},{"key":"8892_CR214","doi-asserted-by":"publisher","first-page":"1207631","DOI":"10.3389\/fimmu.2023.1207631","volume":"14","author":"E Gharib","year":"2023","unstructured":"Gharib E, Veilleux V, Boudreau LH, Pichaud N, Robichaud GA. Platelet-derived microparticles provoke chronic lymphocytic leukemia malignancy through metabolic reprogramming. Front Immunol. 2023;14:1207631.","journal-title":"Front Immunol"},{"issue":"2","key":"8892_CR215","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10555-017-9673-1","volume":"36","author":"MZ Wojtukiewicz","year":"2017","unstructured":"Wojtukiewicz MZ, Sierko E, Hempel D, Tucker SC, Honn KV. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev. 2017;36(2):249\u201362.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"8892_CR216","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1158\/1541-7786.MCR-23-0329","volume":"22","author":"V Veilleux","year":"2024","unstructured":"Veilleux V, Pichaud N, Boudreau LH, Robichaud GA. Mitochondria Transfer by Platelet-Derived Microparticles Regulates Breast Cancer Bioenergetic States and Malignant Features. Mol Cancer Res. 2024;22(3):268\u201381.","journal-title":"Mol Cancer Res"},{"issue":"9","key":"8892_CR217","doi-asserted-by":"publisher","first-page":"113147","DOI":"10.1016\/j.celrep.2023.113147","volume":"42","author":"W Zhang","year":"2023","unstructured":"Zhang W, Zhou H, Li H, Mou H, Yinwang E, Xue Y, Wang S, Zhang Y, Wang Z, Chen T, et al. Cancer cells reprogram to metastatic state through the acquisition of platelet mitochondria. Cell Rep. 2023;42(9):113147.","journal-title":"Cell Rep"},{"issue":"1","key":"8892_CR218","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1186\/s12885-021-08840-2","volume":"21","author":"FJ Hinsenveld","year":"2021","unstructured":"Hinsenveld FJ, Noordman BJ, Boormans JL, Voortman J, van Leenders G, van der Pas SL, van Beek SC, Oprea-Lager DE, Vis AN. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial. BMC Cancer. 2021;21(1):1161.","journal-title":"BMC Cancer"},{"issue":"9","key":"8892_CR219","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ccell.2022.08.006","volume":"40","author":"S in \u2018t Veld","year":"2022","unstructured":"in \u2018t Veld S, Arkani M, Post E, Antunes-Ferreira M, D\u2019Ambrosi S, Vessies DCL, Vermunt L, Vancura A, Muller M, Niemeijer AN, et al. Detection and localization of early- and late-stage cancers using platelet RNA. Cancer Cell. 2022;40(9):999\u2013e10091006.","journal-title":"Cancer Cell"},{"issue":"21\u201322","key":"8892_CR220","doi-asserted-by":"publisher","first-page":"e1900042","DOI":"10.1002\/pmic.201900042","volume":"19","author":"A Kumar","year":"2019","unstructured":"Kumar A, Misra BB. Challenges and Opportunities in Cancer Metabolomics. Proteomics. 2019;19(21\u201322):e1900042.","journal-title":"Proteomics"},{"issue":"12","key":"8892_CR221","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1021\/pr400859w","volume":"12","author":"N Bansal","year":"2013","unstructured":"Bansal N, Gupta A, Mitash N, Shakya PS, Mandhani A, Mahdi AA, Sankhwar SN, Mandal SK. Low- and high-grade bladder cancer determination via human serum-based metabolomics approach. J Proteome Res. 2013;12(12):5839\u201350.","journal-title":"J Proteome Res"},{"key":"8892_CR222","doi-asserted-by":"publisher","first-page":"46176","DOI":"10.1038\/srep46176","volume":"7","author":"G Tan","year":"2017","unstructured":"Tan G, Wang H, Yuan J, Qin W, Dong X, Wu H, Meng P. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer. Sci Rep. 2017;7:46176.","journal-title":"Sci Rep"},{"issue":"6","key":"8892_CR223","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jpha.2022.08.004","volume":"12","author":"K Ossoli\u0144ski","year":"2022","unstructured":"Ossoli\u0144ski K, Ruman T, Copi\u00e9 V, Tripet BP, Nogueira LB, Nogueira K, Ko\u0142odziej A, P\u0142aza-Altamer A, Ossoli\u0144ska A, Ossoli\u0144ski T, et al. Metabolomic and elemental profiling of blood serum in bladder cancer. J Pharm Anal. 2022;12(6):889\u2013900.","journal-title":"J Pharm Anal"},{"key":"8892_CR224","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cca.2014.05.012","volume":"436","author":"N Bansal","year":"2014","unstructured":"Bansal N, Gupta A, Sankhwar SN, Mahdi AA. Low- and high-grade bladder cancer appraisal via serum-based proteomics approach. Clin Chim Acta. 2014;436:97\u2013103.","journal-title":"Clin Chim Acta"},{"key":"8892_CR225","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jpba.2016.02.026","volume":"124","author":"N Bansal","year":"2016","unstructured":"Bansal N, Gupta AK, Gupta A, Sankhwar SN, Mahdi AA. Serum-based protein biomarkers of bladder cancer: A pre- and post-operative evaluation. J Pharm Biomed Anal. 2016;124:22\u20135.","journal-title":"J Pharm Biomed Anal"},{"key":"8892_CR226","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3389\/fonc.2019.01484","volume":"9","author":"AA Elamin","year":"2019","unstructured":"Elamin AA, Klunkelfu\u00df S, K\u00e4mpfer S, Oehlmann W, Stehr M, Smith C, Simpson GR, Morgan R, Pandha H, Singh M. A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection. Front Oncol. 2019;9:1484.","journal-title":"Front Oncol"},{"issue":"10","key":"8892_CR227","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/carcin\/bgy098","volume":"39","author":"A Allione","year":"2018","unstructured":"Allione A, Pardini B, Viberti C, Giribaldi G, Turini S, Di Gaetano C, Guarrera S, Cordero F, Oderda M, Allasia M, et al. MMP23B expression and protein levels in blood and urine are associated with bladder cancer. Carcinogenesis. 2018;39(10):1254\u201363.","journal-title":"Carcinogenesis"},{"key":"8892_CR228","doi-asserted-by":"publisher","first-page":"104329","DOI":"10.1016\/j.jprot.2021.104329","volume":"247","author":"R L\u00f3pez-Cort\u00e9s","year":"2021","unstructured":"L\u00f3pez-Cort\u00e9s R, G\u00f3mez BB, V\u00e1zquez-Est\u00e9vez S, P\u00e9rez-Fentes D, N\u00fa\u00f1ez C. Blood-based protein biomarkers in bladder urothelial tumors. J Proteom. 2021;247:104329.","journal-title":"J Proteom"},{"key":"8892_CR229","doi-asserted-by":"crossref","unstructured":"Alberca-Del Arco F, Prieto-Cuadra D, de la Santos-Perez R, S\u00e1ez-Barranquero F, Matas-Rico E, Herrera-Imbroda B. New perspectives on the role of liquid biopsy in bladder cancer: applicability to precision medicine. Cancers (Basel). 2024;16(4):803.","DOI":"10.3390\/cancers16040803"},{"key":"8892_CR230","doi-asserted-by":"crossref","unstructured":"Ho HY, Chung KK, Kan CM, Wong SC. Liquid biopsy in the clinical management of cancers. Int J Mol Sci. 2024;25(16):8594.","DOI":"10.3390\/ijms25168594"},{"key":"8892_CR231","unstructured":"[https:\/\/clinicaltrials.gov\/]."},{"issue":"670","key":"8892_CR232","doi-asserted-by":"publisher","first-page":"eabo3958","DOI":"10.1126\/scitranslmed.abo3958","volume":"14","author":"V Anagnostou","year":"2022","unstructured":"Anagnostou V, Landon BV, Medina JE, Forde P, Velculescu VE. Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. Sci Transl Med. 2022;14(670):eabo3958.","journal-title":"Sci Transl Med"},{"issue":"24","key":"8892_CR233","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","volume":"393","author":"T Powles","year":"2025","unstructured":"Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Bjerggaard Jensen J, Makaroff L, Jiang S, Ku JH, et al. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. N Engl J Med. 2025;393(24):2395\u2013408.","journal-title":"N Engl J Med"},{"issue":"12","key":"8892_CR234","doi-asserted-by":"publisher","first-page":"111859","DOI":"10.1016\/j.celrep.2022.111859","volume":"41","author":"TN Clinton","year":"2022","unstructured":"Clinton TN, Chen Z, Wise H, Lenis AT, Chavan S, Donoghue MTA, Almassi N, Chu CE, Dason S, Rao P, et al. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep. 2022;41(12):111859.","journal-title":"Cell Rep"},{"issue":"1","key":"8892_CR235","doi-asserted-by":"publisher","first-page":"23128","DOI":"10.1038\/s41598-024-72755-8","volume":"14","author":"M Miyake","year":"2024","unstructured":"Miyake M, Nishimura N, Oda Y, Miyamoto T, Iida K, Tomizawa M, Shimizu T, Owari T, Ohnishi K, Hori S, et al. Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors. Sci Rep. 2024;14(1):23128.","journal-title":"Sci Rep"},{"issue":"5","key":"8892_CR236","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1111\/cas.16146","volume":"115","author":"JS Park","year":"2024","unstructured":"Park JS, Kim H, Jang WS, Kim J, Ham WS, Lee ST. ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy. Cancer Sci. 2024;115(5):1680\u20137.","journal-title":"Cancer Sci"},{"issue":"3","key":"8892_CR237","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cac2.12408","volume":"43","author":"X Wang","year":"2023","unstructured":"Wang X, Zhang S, Jin D, Luo J, Shi Y, Zhang Y, Wu L, Song Y, Su D, Pan Z, et al. \u00b5-opioid receptor agonist facilitates circulating tumor cell formation in bladder cancer via the MOR\/AKT\/Slug pathway: a comprehensive study including randomized controlled trial. Cancer Commun (Lond). 2023;43(3):365\u201386.","journal-title":"Cancer Commun (Lond)"},{"issue":"7","key":"8892_CR238","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1002\/jmv.26846","volume":"93","author":"AA Kojabad","year":"2021","unstructured":"Kojabad AA, Farzanehpour M, Galeh HEG, Dorostkar R, Jafarpour A, Bolandian M, Nodooshan MM. Droplet digital PCR of viral DNA\/RNA, current progress, challenges, and future perspectives. J Med Virol. 2021;93(7):4182\u201397.","journal-title":"J Med Virol"},{"key":"8892_CR239","doi-asserted-by":"crossref","unstructured":"Lin C, Liu X, Zheng B, Ke R, Tzeng CM. Liquid biopsy, ctDNA diagnosis through NGS. Life (Basel). 2021;11(9):890.","DOI":"10.3390\/life11090890"},{"issue":"Suppl 1","key":"8892_CR240","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.4103\/jpbs.jpbs_838_23","volume":"16","author":"JS Mandlik","year":"2024","unstructured":"Mandlik JS, Patil AS, Singh S. Next-Generation Sequencing (NGS): Platforms and Applications. J Pharm Bioallied Sci. 2024;16(Suppl 1):S41\u20135.","journal-title":"J Pharm Bioallied Sci"},{"issue":"7","key":"8892_CR241","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1373\/clinchem.2018.301341","volume":"65","author":"THT Cheng","year":"2019","unstructured":"Cheng THT, Jiang P, Teoh JYC, Heung MMS, Tam JCW, Sun X, Lee WS, Ni M, Chan RCK, Ng CF, et al. Noninvasive Detection of Bladder Cancer by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Cell-Free DNA for Methylation and Copy Number Profiling. Clin Chem. 2019;65(7):927\u201336.","journal-title":"Clin Chem"},{"key":"8892_CR242","doi-asserted-by":"crossref","unstructured":"Francini E, Bleve S, Fanelli GN, Serafini MS, Pederzoli F, Ferri A, Minonne E, Venturini J, Rodrigues S, Pakula H, et al. Circulating cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) in oncology: from technological advances to clinical applications. NPJ Precis Oncol. 2026.","DOI":"10.1038\/s41698-026-01507-w"},{"issue":"5","key":"8892_CR243","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/ajcp\/aqae175","volume":"163","author":"C Quinn","year":"2025","unstructured":"Quinn C, Lerma LA, Zhu A, Monnat RJ Jr., Wright JL, Lockwood CM, Tretiakova MS. Pilot study: Urine cell-free DNA with low-pass whole genome sequencing can detect and molecularly type upper tract urothelial carcinomas. Am J Clin Pathol. 2025;163(5):696\u2013707.","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"8892_CR244","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/clinchem\/hvae156","volume":"70","author":"XY Meng","year":"2024","unstructured":"Meng XY, Zhou XH, Li S, Shi MJ, Li XH, Yang BY, Liu M, Yi KZ, Wang YZ, Zhang HY, et al. Machine Learning-Based Detection of Bladder Cancer by Urine cfDNA Fragmentation Hotspots that Capture Cancer-Associated Molecular Features. Clin Chem. 2024;70(12):1463\u201373.","journal-title":"Clin Chem"},{"issue":"10","key":"8892_CR245","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1172\/JCI38609","volume":"119","author":"T Kojima","year":"2009","unstructured":"Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, Tazawa H, Kyo S, Mizuguchi H, Urata Y, et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest. 2009;119(10):3172\u201381.","journal-title":"J Clin Invest"},{"issue":"44","key":"8892_CR246","doi-asserted-by":"publisher","first-page":"71330","DOI":"10.18632\/oncotarget.11114","volume":"7","author":"F Gao","year":"2016","unstructured":"Gao F, Cui Y, Jiang H, Sui D, Wang Y, Jiang Z, Zhao J, Lin S. Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget. 2016;7(44):71330\u201340.","journal-title":"Oncotarget"},{"key":"8892_CR247","doi-asserted-by":"publisher","first-page":"821454","DOI":"10.3389\/fonc.2022.821454","volume":"12","author":"B Hu","year":"2022","unstructured":"Hu B, Gong Y, Wang Y, Xie J, Cheng J, Huang Q. Comprehensive Atlas of Circulating Rare Cells Detected by SE-iFISH and Image Scanning Platform in Patients With Various Diseases. Front Oncol. 2022;12:821454.","journal-title":"Front Oncol"},{"key":"8892_CR248","doi-asserted-by":"crossref","unstructured":"Rushton AJ, Nteliopoulos G, Shaw JA, Coombes RC. A review of circulating tumour cell enrichment technologies. Cancers (Basel). 2021;13(5):970.","DOI":"10.3390\/cancers13050970"},{"issue":"3","key":"8892_CR249","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.molonc.2015.12.002","volume":"10","author":"KC Andree","year":"2016","unstructured":"Andree KC, van Dalum G, Terstappen LW. Challenges in circulating tumor cell detection by the CellSearch system. Mol Oncol. 2016;10(3):395\u2013407.","journal-title":"Mol Oncol"},{"key":"8892_CR250","doi-asserted-by":"crossref","unstructured":"Sidhom K, Obi PO, Saleem A. A review of Exosomal isolation methods: is size exclusion chromatography the best option? Int J Mol Sci. 2020;21(18).","DOI":"10.3390\/ijms21186466"},{"key":"8892_CR251","doi-asserted-by":"publisher","first-page":"811971","DOI":"10.3389\/fbioe.2021.811971","volume":"9","author":"J Chen","year":"2021","unstructured":"Chen J, Li P, Zhang T, Xu Z, Huang X, Wang R, Du L. Review on Strategies and Technologies for Exosome Isolation and Purification. Front Bioeng Biotechnol. 2021;9:811971.","journal-title":"Front Bioeng Biotechnol"},{"key":"8892_CR252","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ymeth.2016.09.010","volume":"118\u2013119","author":"C Meyer","year":"2017","unstructured":"Meyer C, Garzia A, Tuschl T. Simultaneous detection of the subcellular localization of RNAs and proteins in cultured cells by combined multicolor RNA-FISH and IF. Methods. 2017;118\u2013119:101\u201310.","journal-title":"Methods"},{"issue":"1","key":"8892_CR253","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2144\/99261rv01","volume":"26","author":"WM Freeman","year":"1999","unstructured":"Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls and potential. Biotechniques. 1999;26(1):112\u201322. 124\u2009\u2013\u2009115.","journal-title":"Biotechniques"},{"key":"8892_CR254","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-12-420037-1.00003-8","volume":"530","author":"SL He","year":"2013","unstructured":"He SL, Green R. Northern blotting. Methods Enzymol. 2013;530:75\u201387.","journal-title":"Methods Enzymol"},{"issue":"6","key":"8892_CR255","doi-asserted-by":"publisher","first-page":"13259","DOI":"10.3390\/ijms160613259","volume":"16","author":"MO Urbanek","year":"2015","unstructured":"Urbanek MO, Nawrocka AU, Krzyzosiak WJ. Small RNA Detection by in Situ Hybridization Methods. Int J Mol Sci. 2015;16(6):13259\u201386.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"8892_CR256","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13045-020-01005-x","volume":"13","author":"M Hong","year":"2020","unstructured":"Hong M, Tao S, Zhang L, Diao LT, Huang X, Huang S, Xie SJ, Xiao ZD, Zhang H. RNA sequencing: new technologies and applications in cancer research. J Hematol Oncol. 2020;13(1):166.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"8892_CR257","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41585-025-01023-9","volume":"22","author":"SV Lindskrog","year":"2025","unstructured":"Lindskrog SV, Strandgaard T, Nordentoft I, Galsky MD, Powles T, Agerb\u00e6k M, Jensen JB, Alix-Panabi\u00e8res C, Dyrskj\u00f8t L. Circulating tumour DNA and circulating tumour cells in bladder cancer - from discovery to clinical implementation. Nat Rev Urol. 2025;22(9):590\u2013608.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"8892_CR258","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.eururo.2024.05.014","volume":"86","author":"I Nordentoft","year":"2024","unstructured":"Nordentoft I, Lindskrog SV, Birkenkamp-Demtr\u00f6der K, Gonzalez S, Kuzman M, Levatic J, Glavas D, Ptashkin R, Smadbeck J, Afterman D, et al. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma. Eur Urol. 2024;86(4):301\u201311.","journal-title":"Eur Urol"},{"issue":"5","key":"8892_CR259","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.urolonc.2018.02.004","volume":"36","author":"R Azevedo","year":"2018","unstructured":"Azevedo R, Soares J, Peixoto A, Cotton S, Lima L, Santos LL, Ferreira JA. Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology. Urol Oncol. 2018;36(5):221\u201336.","journal-title":"Urol Oncol"},{"issue":"2","key":"8892_CR260","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrurol.2016.224","volume":"14","author":"MA Gorin","year":"2017","unstructured":"Gorin MA, Verdone JE, van der Toom E, Bivalacqua TJ, Allaf ME, Pienta KJ. Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. Nat Rev Urol. 2017;14(2):90\u20137.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"8892_CR261","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.juro.2014.05.050","volume":"192","author":"JM Street","year":"2014","unstructured":"Street JM, Yuen PS, Star RA. Bioactive exosomes: possibilities for diagnosis and management of bladder cancer. J Urol. 2014;192(2):297\u20138.","journal-title":"J Urol"},{"key":"8892_CR262","doi-asserted-by":"crossref","unstructured":"Ahn JH, Kang CK, Kim EM, Kim AR, Kim A. Proteomics for early detection of non-muscle-invasive bladder cancer: clinically useful urine protein biomarkers. Life (Basel). 2022;12(3):395.","DOI":"10.3390\/life12030395"},{"issue":"5","key":"8892_CR263","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1586\/epr.09.70","volume":"6","author":"S Goodison","year":"2009","unstructured":"Goodison S, Rosser CJ, Urquidi V. Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Rev Proteom. 2009;6(5):507\u201314.","journal-title":"Expert Rev Proteom"},{"issue":"26","key":"8892_CR264","doi-asserted-by":"publisher","first-page":"23592","DOI":"10.1021\/acsnano.5c01197","volume":"19","author":"H Guo","year":"2025","unstructured":"Guo H, Jin B, Zhu Z, Dai X, Wang M, Xie Y, Xu C, Wang Z, Liu Y, Tan W. Nanoparticle-Protein Corona Boosted Cancer Diagnosis with Proteomic Transfer Learning. ACS Nano. 2025;19(26):23592\u2013605.","journal-title":"ACS Nano"},{"issue":"1","key":"8892_CR265","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41467-025-56337-4","volume":"16","author":"X Liu","year":"2025","unstructured":"Liu X, Sun H, Hou X, Sun J, Tang M, Zhang YB, Zhang Y, Sun W, Liu C. Standard operating procedure combined with comprehensive quality control system for multiple LC-MS platforms urinary proteomics. Nat Commun. 2025;16(1):1051.","journal-title":"Nat Commun"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08892-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08892-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08892-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:16:32Z","timestamp":1791933392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08892-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":265,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8892"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08892-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1294"}}